Want to see ELDN full AI Analyst Report?
ELDN Stock Chart & Stats
$3.32
-$0.02(-0.56%)
At close: 4:00 PM EDT
$3.32
-$0.02(-0.56%)
Day’s Range― - ―
52-Week Range$1.35 - $4.60
Previous CloseN/A
Volume630.04K
Average Volume (3M)997.48K
Market Cap
$242.97M
Enterprise Value$398.44
Total Cash (Recent Filing)$88.76M
Total Debt (Recent Filing)$467.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume1,048,002
30 Day Avg. Volume997,476
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside186.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces interest and solvency pressure while Eledon funds clinical development. This gives the company more flexibility than a highly leveraged biotech, although continued losses still require careful capital management.
Leadership And Governance ContinuityMulti-year director appointments and auditor ratification support continuity in oversight during a critical clinical-development period. Stable governance can help maintain strategic focus and investor confidence as the company advances tegoprubart.
Capital-Raising FlexibilityThe larger share authorization provides structural flexibility to fund trials, pursue transactions, or support future initiatives. It does not create revenue, but it may help Eledon secure capital needed to advance its clinical pipeline.
Bears Say
No Commercial RevenueEledon remains entirely dependent on financing and clinical progress because it has no reported product revenue. Persistent, substantial losses show the business is still distant from self-funded operations and commercial breakeven.
Persistent Cash BurnHeavy operating and free-cash-flow consumption limits the company’s financial runway and increases dependence on external funding. Unless development spending produces a partnership or approved product, additional capital is likely needed to sustain operations.
Shrinking Equity Base And Dilution RiskA declining equity base reflects accumulated losses, while expanded share authorization increases the capacity for future equity issuance. Together, these factors raise the risk of dilution and may reduce existing holders’ economic participation.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.35 and its highest was $4.60 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is $242.97M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 75 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.112.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.18.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 81,261,154 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -4.324%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (186.14% Upside)
$9.50 (186.14% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 70.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$9.50
▲(186.14% Upside)
Technical Analysis
Ownership Overview
0.34% Insiders
7.63% Mutual Funds
24.73% Other Institutional Investors
57.62% Public Companies and
Individual Investors